Latest News About Lilly

Here are the latest Eli Lilly (LLY) news highlights I found recently:

• Major strategic moves: Lilly reportedly pursuing acquisitions and collaborations to expand its neuroscience and oncology pipelines, including discussions around a potential acquisition of Centessa Pharmaceuticals and partnerships with other biotech firms. This indicates a shift to broaden therapy areas and accelerate development timelines.[1]

• Q1 2026 results on the horizon: Lilly scheduled its first-quarter 2026 financial results release for April 30, 2026, with an investor conference call to follow. This event typically includes updates on product performance, pipeline progress, and financial outlook.[1]

• Regulatory and product milestones: The company has been active in pursuing regulatory submissions and potential approvals for its diabetes and weight-management initiatives, including ongoing or upcoming FDA interactions.[3][1]

• Global manufacturing and expansion: Reports indicate Lilly’s continued investments in manufacturing capacity and supply chain expansion, aiming to support demand for key assets like tirzepatide-based products and other franchises.[4][1]

If you’d like, I can narrow this to a specific area (e.g., regulatory news, pipeline updates, or financial results) or pull the very latest headlines from a few trusted outlets and present them in a concise digest. I can also monitor for updates and provide a brief summary as new items appear.